FDA of­fers pos­i­tive sig­nals for po­ten­tial pe­di­atric neu­rob­las­toma drug ahead of ODAC meet­ing

The FDA’s On­co­log­ic Drugs Ad­vi­so­ry Com­mit­tee to­mor­row will re­view US WorldMeds’ po­ten­tial high-risk pe­di­atric neu­rob­las­toma drug to re­duce the risk of re­lapse af­ter front-line ther­a­py …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER